[{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"AFM13","moa":"CD30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AFM24","moa":"ErbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AFM13","moa":"CD30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AFM24","moa":"ErbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AFM24","moa":"ErbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AFM13-NK cells","moa":"CD30","graph1":"Oncology","graph2":"Phase I","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AFM13","moa":"CD30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"NKMax","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"AFM24","moa":"EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Affimed \/ Affimed","highestDevelopmentStatusID":"4","companyTruncated":"Affimed \/ Affimed"},{"orgOrder":0,"company":"Affimed","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AFM13","moa":"CD30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Affimed \/ Gilead","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Gilead"},{"orgOrder":0,"company":"Affimed","sponsor":"Roivant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"AFM32","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affimed","amount2":2.0600000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":2.0600000000000001,"dosageForm":"","sponsorNew":"Affimed \/ Roivant Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Affimed \/ Roivant Sciences"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AFM13-NK cells","moa":"CD30","graph1":"Oncology","graph2":"Phase I","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AFM13","moa":"CD30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Affimed \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Merck"},{"orgOrder":0,"company":"Affimed","sponsor":"Silicon Valley Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2021","type":"Financing","leadProduct":"AFM13","moa":"CD30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Affimed \/ Silicon Valley Bank","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Silicon Valley Bank"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"AFM13","moa":"CD30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"AFM24","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"AFM13","moa":"CD30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AFM13","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AFM13","moa":"CD30","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Affimed \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AFM24","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AFM13","moa":"CD30\/CD16A","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Adoptive NK-cell Therapy","moa":"CD30\/CD16A","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AFM28","moa":"CD123\/CD16A","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AFM24","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AFM24","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AFM28","moa":"CD123\/CD16A","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AFM24","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AFM24","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Artiva Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"AB-101","moa":"CD30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Artiva Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Artiva Biotherapeutics"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AFM28","moa":"CD123\/CD16A","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AFM13","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AFM28","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"AFM13","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"AFM28","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Artiva Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"AB-101","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Artiva Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Artiva Biotherapeutics"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"AB-101","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"AFM24","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"AFM24","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"M.D. Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Acimtamig","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ M.D. Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ M.D. Anderson Cancer Center"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"AFM24","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"AFM24","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"AFM24","moa":"","graph1":null,"graph2":null,"graph3":"Affimed","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Affimed \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Affimed
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
